[Translation] One study in Chinese patients with International Prognostic Scoring System (IPSS) intermediate-2 and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia or acute myeloid leukemia with 20-30% blasts and multilineage dysplasia A prospective/retrospective non-interventional study of VIDAZA® (azacitidine) conducted
本研究是一项回顾性和前瞻性、非干预性、多中心研究,将评估在常规医疗实践条件下,按照中国产品说明书接受阿扎胞苷(AZA)治疗的中危-2(Int-2)和高危骨髓增生异常综合征(MDS)(根据IPSS确定)或慢性粒单核细胞白血病(CMML)或伴20-30%骨髓(BM)原始细胞和多系发育异常的急性髓系白血病(AML)的(根据WHO分类确定)患者在真实世界环境中(包括住院和门诊环境)的安全性和有效性。
[Translation] This study is a retrospective and prospective, non-interventional, multicenter study that will evaluate intermediate-risk-2 (Int-2) patients treated with azacitidine (AZA) according to Chinese product labeling under routine medical practice conditions. ) and high-risk myelodysplastic syndrome (MDS) (as determined by IPSS) or chronic myelomonocytic leukemia (CMML) or acute myeloid leukemia (AML) with 20-30% bone marrow (BM) blasts and multilineage dysplasia ) (as determined by WHO classification) in patients in real-world settings, including inpatient and outpatient settings, for safety and efficacy.